Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Endocrine
Published in: Endocrine 1/2019

01-10-2019 | Thyrotoxicosis | Review

Thyroid hormone misuse and abuse

Author: Victor J. Bernet

Published in: Endocrine | Issue 1/2019

Login to get access

Abstract

Thyroid hormone (TH) plays an essential role in human physiology and maintenance of appropriate levels is important for good health. Unfortunately, there are instances in which TH is misused or abused. Such misuse may be intentional such as when individuals take thyroid hormone for unapproved indications like stimulation of weight loss or improved energy. There are instances where healthcare providers prescribe thyroid hormone for controversial or out of date uses and sometimes in supraphysiologic doses. Othertimes, unintentional exposure may occur through supplements or food that unknowingly contain TH. No matter the reason, exposure to exogenous forms of TH places the public at risk for potential adverse side effects.
Literature
1.
E.H. Hume, The contributions of China to the science and art of medicine. Science. 59, 345–350 (1924)CrossRefPubMed
2.
E.C. Kendall, The isolation in crystalline form of the compound containing iodin, which occurs in the thyroid. Its chemical nature and physiologic activity. JAMA 21(15), 2045–2046 (1983)CrossRef
3.
4.
5.
D. Schultheiss, J. Denil, U. Jonas, Rejuvenation in the early 20th century. Andrologia. 29(6), 351–355 (1997)CrossRefPubMed
6.
7.
K. Sterling, S. Refetoff, H.A. Selenkow, T3 thyrotoxicosis. Thyrotoxicosis due to elevated serum triiodothyronine levels. JAMA 27(4), 571–575 (1970)CrossRef
8.
Dietary Supplement Health and Education Act of 1994. Pub L N0. 103-417, 21 USC § 3419
9.
A.M. Abe, D.J. Hein, P.J. Gregory, Regulatory alerts for dietary supplements in Canada and the United States, 2005–13. Am. J. Health Syst. Pharm. 1(11), 966–971 (2015)CrossRef
10.
B.B. Timbo, M.P. Ross, P.V. McCarthy, C.T. Lin, Dietary supplements in a national survey: prevalence of use and reports of adverse events. J. Am. Diet. Assoc. 106(12), 1966–1974 (2006)CrossRefPubMed
11.
K.M. Wilson, J.D. Klein, T.S. Sesselberg, S.M. Yussman, D.B. Markow, A.E. Green, J.C. West, N.J. Gray, Use of complementary medicine and dietary supplements among U.S. adolescents. J. Adolesc. Health 38(4), 385–394 (2006)CrossRefPubMed
12.
P.A. Cohen, Hazards of hindsight-monitoring the safety of nutritional supplements. N. Engl. J. Med. 370(14), 1277–1280 (2014)CrossRefPubMed
13.
14.
C.E. Carvey, E.K. Farina, H.R. Lieberman, Confidence in the efficacy and safety of dietary supplements among United States active duty army personnel. BMC Complement. Alter. Med. 10(1), 182–194 (2012)
15.
A. Dickinson, J. Blatman, N. El-Dash, J.C. Franco, Consumer usage and reasons for using dietary supplements: report of a series of surveys. J. Am. Coll. Nutr. 33(2), 176–82 (2014)CrossRefPubMed
16.
17.
G.W. Neuberg, K.E. Stephenson, D.A. Sears, R.J. McConnell, Internet-enabled thyroid hormone abuse. Ann. Intern Med. 6(1), 60–61 (2009)CrossRef
18.
G.A. Bray, K.E. Melvin, I. Chopra, Effect of triiodothyronine on some metabolic responses of obese patients. Am. J. Clin. Nutr. 26(7), 715–721 (1973)CrossRefPubMed
19.
G.D. Braunstein, R. Koblin, M. Sugawara, A.E. Pekary, J.M. Hershman, Unintentional thyrotoxicosis factitia due to a diet pill. West J. Med. 145(3), 388–391 (1986)PubMedPubMedCentral
20.
C.T. Sawin, M.H. London, ‘Natural’ desiccated thyroid. A ‘health-food’ thyroid preparation. Arch. Intern. Med. 149(9), 2117–2118 (1989)CrossRefPubMed
21.
G.H. Daniels, P. Sluss, Pure T3-thyrotoxicosis from a Mexican weight losssupplement. Endocr. Pract. 19(3), 559–560 (2013)PubMed
22.
G.Y. Kang, J.R. Parks, B. Fileta, A. Chang, M.M. Abdel-Rahim, H.B. Burch, V.J. Bernet, Thyroxine and triiodothyronine content in commercially available thyroid health supplements. Thyroid 23(10), 1233–1237 (2013)CrossRefPubMed
23.
H.K. Akturk, A.M. Chindris, J.M. Hines, R.J. Singh, V.J. Bernet, Over-the-counter “adrenal support” supplements contain thyroid and steroid-based adrenal hormones. Mayo Clin. Proc. 933, 284–290 (2018)CrossRef
24.
C.D. Seger, X. He, L.E. Braverman, M.W. Yeh, V.J. Bernet, R.J. Singh, C.M. Rhee, A.M. Leung, Negligible thyroid hormone content present in nonprescription U.S. Weight Loss Products. Thyroid 27(2), 300–301 (2017)CrossRefPubMedPubMedCentral
25.
G. Brenta, S. Danzi, I. Klein, Potential therapeutic applications of thyroid hormone analogs. Nat. Clin. Pr. Endocrinol. Metab. 3(9), 632–640 (2007)CrossRef
26.
G. Radetti, L. Persani, G. Molinaro, D. Mannavola, D. Cortelazzi, V.K. Chatterjee, P. Beck-Peccoz, Clinical and hormonal outcome after two years of triiodothyroacetic acid treatment in a child with thyroid hormone resistance. Thyroid. 7(5), 775–778 (1997)CrossRefPubMed
27.
M. Moreno, P. de Lange, A. Lombardi, E. Silvestri, A. Lanni, F. Goglia, Metabolic effects of thyroid hormone derivatives. Thyroid. 18(2), 239–253 (2008)CrossRefPubMed
28.
B.A. Bauer, P.L. Elkin, D. Erickson, G.G. Klee, M.D. Brennan, Symptomatic hyperthyroidism in a patient taking the dietary supplement tiratricol. Mayo Clin. Proc. 77(6), 587–590 (2002)CrossRefPubMed
29.
Food and Drug Administration. FDA warns against consuming dietary supplements containing tiratricol (National Press Office: Talk Paper, Rockville, MD, 1999)
30.
J. Cohen-Lehman, M.M. Charitou, I. Klein, Tiratricol-induced periodic paralysis: a review of nutraceuticals affecting thyroid function. Endocr. Pract. 17(4), 610–615 (2011)CrossRefPubMed
31.
Y.C. Chen, J.T. Fang, C.T. Chang, H.H. Chou, Thyrotoxic periodic paralysis in a patient abusing thyroxine for weight reduction. Ren. Fail. 23(1), 139–142 (2001)CrossRefPubMed
32.
M.C. Scally, A. Hodge, A report of hypothyroidism induced by an over-the-counter fat loss supplement (Tiratricol). Int J. Sport Nutr. Exerc Metab. 13(1), 112–116 (2003)CrossRefPubMed
33.
34.
K.M. Allen, V.B. Crawford, J.V. Conaglen, M.S. Elston, Case report: clues to the diagnosis of an unsuspected massive levothyroxine overdose. CJEM 17(6), 692–698 (2015)CrossRefPubMed
35.
B. Nygaard, E.A. Saedder, K. Dalhoff, M. Wikkelsoe, G. Jürgens, Levothyroxine poisoning—symptoms and clinical outcome. Basic Clin. Pharm. Toxicol. 117(4), 280–285 (2015)
36.
S. Bhasin, W. Wallace, J.B. Lawrence, M. Lesch, Sudden death associated with thyroid hormone abuse. Am. J. Med. 71(5), 887–890 (1981)CrossRefPubMed
37.
J.B. Mowry, D.A. Spyker, L.R. Cantilena Jr, J.E. Bailey, M. Ford, 2012 annual report of the American association of poison control centers’ national poison data system (NPDS): 30th annual report. Clin. Toxicol. (Philos.). 51(10), 949–1229 (2013)CrossRef
38.
J.H. Cohen 3rd, S.H. Ingbar, L.E. Braverman, Thyrotoxicosis due to ingestion of excess thyroid hormone. Endocr. Rev. 10(2), 113–124 (1989)CrossRefPubMed
39.
Plummer H. Tr. Assn. Am. Phys. 46, 171 (1931)
40.
J.F. Dymling, D.V. Becker, Occurrence of hyperthyroidism in patients receiving thyroid hormone. J. Clin. Endocrinol. Metab. 27, 1487–1491 (1967)CrossRefPubMed
41.
C.W. Hedberg, D.B. Fishbein, R.S. Janssen, B. Meyers, J.M. McMillen, K.L. MacDonald, K.E. White, L.J. Huss, E.S. Hurwitz, J.R. Farhie, J.L. Simmons, L.E. Braverman, An outbreak of thyrotoxicosis caused by the consumption of bovine thyroid gland in ground beef. N. Engl. J. Med. 16(316), 993–998 (1987)CrossRef
42.
M.S. Parmar, C. Sturge, Recurrent hamburger thyrotoxicosis. CMAJ 2(5), 415–417 (2003)
43.
N.D. Brayshaw, D.D. Brayshaw, Thyroid hypofunction in premenstrual syndrome. N. Engl. J. Med. 4(23), 1486–1487 (1986)
44.
T.F. Nikolai, G.M. Mulligan, R.K. Gribble, P.G. Harkins, P.R. Meier, R.C. Roberts, Thyroid function and treatment in premenstrual syndrome. J. Clin. Endocrinol. Metab. 70(4), 1108–1113 (1990)CrossRefPubMed
45.
W.F. Young Jr, C.A. Gorman, N.S. Jiang, D. Machacek, I.D. Hay, L-thyroxine contamination of pharmaceutical D-thyroxine: probable cause of therapeutic effect. Clin. Pharm. Ther. 36(6), 781–787 (1984)CrossRef
46.
X. Zhou, A.V. Ravindran, B. Qin, C. Del Giovane, Q. Li, M. Bauer, Y. Liu, Y. Fang, T. da Silva, Y. Zhang, L. Fang, X. Wang, P. Xie, Comparative efficacy, acceptability, and tolerability of augmentation agents in treatment-resistant depression: systematic review and network meta-analysis. J. Clin. Psychiatry 76(4), e487–e498 (2015)CrossRefPubMed
47.
R. Aronson, H.J. Offman, R.T. Joffe, C.D. Naylor, Triiodothyronine augmentation in the treatment of refractory depression. A meta-analysis. Arch. Gen. Psychiatry 53(9), 842–848 (1996)CrossRefPubMed
48.
T. Parmentier, P. Sienaert, The use of triiodothyronine (T3) in the treatment of bipolar depression: a review of the literature. J. Affect Disord. 15(229), 410–414 (2018)CrossRef
49.
50.
L. Wartofsky, K.D. Burman, Alterations in thyroid function in patients with systemic illness: the “euthyroid sick syndrome”. Endocr. Rev. 3(2), 164–217 (1982)CrossRefPubMed
51.
R.A. Becker, G.M. Vaughan, M.G. Ziegler, L.G. Seraile, I.W. Goldfarb, E.H. Mansour, W.F. McManus, B.A. Pruitt Jr, A.D. Mason Jr., Hypermetabolic low triiodothyronine syndrome of burn injury. Crit. Care Med. 10(12), 870–875 (1982)CrossRefPubMed
52.
D. Novitzky, D.K. Cooper, C.I. Barton, A. Greer, J. Chaffin, J. Grim, N. Zuhdi, Triiodothyronine as an inotropic agent after open heart surgery. J. Thorac. Cardiovasc Surg. 98(5 Pt 2), 972–977 (1989)PubMed
53.
G.A. Brent, J.M. Hershman, Thyroxine therapy in patients with severe nonthyroidal illnesses and low serum thyroxine concentration. J. Clin. Endocrinol. Metab. 63(1), 1–8 (1986)CrossRefPubMed
54.
S. Lee, A.P. Farwell, Euthyroid sick syndrome. Compr. Physiol. 15(2), 1071–1080 (2016)CrossRef
55.
56.
57.
A. Bains, A.J. Brosseau, D. Harrison, Iatrogenic thyrotoxicosis secondary to compounded liothyronine. Can. J. Hosp. Pharm. 68(1), 57–59 (2015)PubMedPubMedCentral
58.
V. Ioos, V. Das, E. Maury, J.L. Baudel, J. Guéchot, B. Guidet, G. Offenstadt, A thyrotoxicosis outbreak due to dietary pills in Paris. Ther. Clin. Risk Manag. 4(6), 1375–1379 (2008)PubMedPubMedCentral
Metadata
Title
Thyroid hormone misuse and abuse
Author
Victor J. Bernet
Publication date
01-10-2019
Publisher
Springer US
Keyword
Thyrotoxicosis
Published in
Endocrine / Issue 1/2019
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-019-02045-1

Other articles of this Issue 1/2019

Endocrine 1/2019 Go to the issue

Review

Thyroid hormone therapy of hypothyroidism in pregnancy

Mini Review

Thyroxine and treatment of hypothyroidism: seven decades of experience

Review

Thyroid hormone therapy for subclinical hypothyroidism

Editorial

Thyroid hormone therapy: past, present, and future

Review

Thyroid hormone metabolites and analogues

Mini Review

Novel thyroid hormones
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits